Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe

Scientists Create Technology to Target ‘Undruggable’ Diseases

February 8, 2016 By Business Wire

City of Hope researchers have announced game-changing technology to chemically modify antibodies (Abs) so that they can cross cell membranes to disable disease-causing proteins inside cells, a feat long-sought by researchers worldwide. The new technology is expected to lead to never-before-imagined targeted treatments for some of the most intractable diseases.

To date, drug companies had been reluctant to put effort into developing therapies that target intracellular factors, simply because they couldn’t get them inside cells. That is, the targets were “undruggable.” The new technology allows for such targeting and has already been licensed to San Diego-based Sorrento Therapeutics, which with City of Hope has created a new company, LA Cell Inc., to pioneer this new class of antibodies.

The technology was invented by Andreas Herrmann, Ph.D., associate research professor, and Hua Eleanor Yu, Ph.D., the Billy and Audrey L. Wilder Professor in Tumor Immunotherapy at City of Hope and co-leader of the Cancer Immunotherapeutics Program. “This novel technology has the potential to revolutionize medicine,” Yu said. “Antibodies that can penetrate the cell could be used to treat what up until now have been incurable diseases, including deadly malignancies like pancreatic cancer and even infectious diseases like HIV.”

Yu and Herrmann discovered that Abs could be chemically modified to allow passage into a cell’s interior, or cytoplasm, without compromising their ability to recognize specific targets. They have tested the technology to modify a number of Abs to recognize several critical cancer-causing oncoproteins, including STAT3, which is activated in a majority of human cancers.

“Treatment with the modified STAT3 antibodies significantly slowed tumor growth in animal models of cancer and prevented STAT from binding DNA,” said Herrmann. “The unmodified antibodies didn’t even penetrate cultured tumor cells.”

The new technology puts STAT3 and other previously undruggable targets within reach of therapeutics. Among those is Myc, the “granddaddy” of all oncoproteins (characterized in lymphoma 25 years ago, Myc is a subject of more than 23,000 scientific papers). High levels of Myc, which like STAT3 is a transcription factor, likely keep cells uncontrollably dividing in half of all cancers, including breast, prostate and gastrointestinal tumors, in addition to lymphoma.

City of Hope’s cell-penetrating antibody technology and Sorrento’s track record of producing fully humanized antibodies puts that brass ring within reach. “This new method to harness the inherent specificity of antibodies against antigens inside cells could transform the field of biomedical research and benefit patients worldwide who are in need of new and effective immunotherapies,” said Steven T. Rosen, provost and chief scientific officer at City of Hope.

“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe